1）Hansson L, Lindholm LH, Niskanen L, et
al. Effect of angiotensin-converting-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hypertension: the
Captopril Prevention Project（CAPPP）randomised trial. Lancet 1999;353:611-6.
2）The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on
cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
3）Heart Outcomes Prevention Evaluation（HOPE）Study Investigators.
Effects of ramipril on cardiovascular and microvascular outcomes in
people with diabetes mellitus: results of the HOPE study and MICRO-HOPE
substudy. Lancet 2000; 355:253-9.
4）Blood Pressure Lowering Treatment Traialists’Collabora-tion.
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of randomised trails.
Lancet; 2000; 356:1955-64.
5）Hansson L, Zanchetti A, Carruthers SG et al. for the
HOT Study Group. Effects of intensive blood-pressure lowering and acetylsalicylic
acid in patients with hypertension: principal results of the Hypertension
Optimal Treatment（HOT）randomized trial. Lancet1998;351:1755-62.
6）Staessen JA, Fagard R, Thijs L,et al. Randomised double-blind
comparison of placebo and active treatment for older patients with isolated
systolic hypertension. Lancet 1997;350:757-64.
7）Pahor M, Psaty BM, Alderman MH, et al. Health outcomes
associated with calcium antagonists compared with other first-line antihypertensive
therapies: a meta-analysis of randomised controlled trials. Lancet 2000;
356:1949-54.
8）Hansson L, Lindholm LH, Ekbom T, et al. for the STOP-Hypertension-2
study group. Randomised trial of old and new antihypertensive drugs
in elderly patients. cardiovascular mortality and morbidity the Swedish
Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
9）Brown MJ, Palmer CR, Castaigne A, et al. Morbidity
and mortality in patients randomised to double-blind treament with a
long-acting calcium-channel blocker or diuretic in the International
Nifedipine GITS study: intervention as a Goal in Hypertension Treatment（INSIGHT）.
Lancet 2000;356:366-72.
10）Hansson L, Hedner T, Lund-Johansen P, et al. Randomised
trial of effects of calcium antagonists compared with diuretics and
β-blockers on cardiovascular morbidity and mortality in hypertension:
the Nordic Diltiazem （NORDIL）study. Lancet 2000;356:359-65.
11）Estacio RO, Jeffers BW, Hiatt WR, et al. The effect
of nisoldipine as compared with enalapril on cardiovascular outcomes
in patients with non-insulin-dependent diabetes and hypertension. N
Engl J Med 1998;338:645-52.
12）Tatti P, Pahor M, Byngton RP, et al. Outcome results
of the fosinopril versus amlodipine cardiovascular events randomized
trial（FACET）in patients with hypertension and diabetes. Diabetes Care
1998;21:597-603.
13）Pitt B, Poole-Wilson PA, Segal R, et al. Effect of
losartan compared with captopril on mortality in patients with symptomatic
heart failure: randomised trial-the losartan heart failure survival
study ELITE II. Lancet 2000;355:1582-7.
14）Muirhead N, Feagna BF, Mahon J, et al. The effect
of valsartan and captopril on reducing microalbuminuria in patients
with type 2 diabetes mellitus: a placebo-controlled trial. Curr Therap
Res 1999;60:650-60.
15）National intervention cooperative study in elderly
hypertensive study group. Randomised double-blind comparison of a calcium
antagonist and a diuretic in elderly hypertensives. Hypertension 1999;34:1129-33.
16）片山茂裕，吉川隆一，田嶼尚子ほか.インスリン依存型糖尿病患者における腎症の治療薬の開発研究. 糖尿病
2000;43（suppl 1）:S269.
17）今井潤. 家庭血圧・自由行動下血圧の標準値. Ther Res 1998;19:72-9.